KEGG   DRUG: Bemarituzumab
Entry
D13029                      Drug                                   
Name
Bemarituzumab (INN);
Bemarituzumab (genetical recombination) (JAN)
Formula
C6376H9850N1698O2012S42
Exact mass
143740.8914
Mol weight
143829.41
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT TYNVHWVRQA PGQGLEWIGS IYPDNGDTSY
NQNFKGRATI TADKSTSTAY MELSSLRSED TAVYYCARGD FAYWGQGTLV TVSSASTKGP
SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS
SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF
SCSVMHEALH NHYTQKSLSL SPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASQGVS NDVAWYQQKP GKAPKLLIYS ASYRYTGVPS
RFSGSGSGTD FTFTISSLQP EDIATYYCQQ HSTTPYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H141-H197, H217-L214, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'141-H'197, H'217-L'214, H'258-H'318, H'364-H'422, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03208  FGFR inhibitor
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Type
Monoclonal antibody
Target
FGFR2 (CD332) [HSA:2263] [KO:K05093]
  Pathway
hsa05200  Pathways in cancer
Interaction
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03208  FGFR inhibitor
     D13029  Bemarituzumab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   FGFR family
    FGFR2 (CD332)
     D13029  Bemarituzumab (INN)
Other DBs
CAS: 1952272-74-0
PubChem: 505120118
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system